SCHEMBL5568231

SCHEMBL5568231

Cc1cccc2c(Nc3cccc(Cl)c3)ncnc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.64
FADS1 O60427 2/20 0.64
LCK P06239 2/20 0.63
TTBK1 Q5TCY1 1/20 0.58
TTBK2 Q6IQ55 1/20 0.58
ERBB2 P04626 2/20 0.57
KDM4E B2RXH2 3/20 0.56
MAPT P10636 3/20 0.56
MEN1 O00255 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP3A4 P08684 2/20 0.56
CYP2D6 P10635 2/20 0.56
KMT2A Q03164 2/20 0.56
NPC1 O15118 1/20 0.56
PRNP P04156 1/20 0.56
CYP2C9 P11712 1/20 0.56
CYP2C19 P33261 1/20 0.56
HTT P42858 1/20 0.56
ABL1 P00519 3/20 0.56
ABL2 P42684 3/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5568069 0.86 JAK2 (0.56) EGFRFADS1LCKTTBK1TTBK2
SCHEMBL9017044 0.86 EGFR (0.68) EGFRFADS1LCKTTBK1TTBK2
SCHEMBL5564578 0.85 MAPT (0.55) EGFRFADS1LCKERBB2MAPT
SCHEMBL5565322 0.85 AURKA (0.52) EGFRFADS1LCKERBB2MAPT
Hydrochloric Acid SCHEMBL11091908 0.84 EGFR (0.68) EGFRFADS1LCKTTBK1TTBK2
SCHEMBL5569470 0.84 EGFR (0.58) EGFRTTBK1TTBK2ERBB2KDM4E
SCHEMBL4787336 0.83 EGFR (0.64) EGFRFADS1LCKTTBK1TTBK2
SCHEMBL5569425 0.83 EGFR (0.72) EGFRERBB2MAPK1FBP1
SCHEMBL5569119 0.82 TP53 (0.50) EGFRFADS1LCKMAPTTP53
SCHEMBL17532922 0.81 EGFR (0.72) EGFRFADS1LCKERBB2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US claimed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP claimed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO claimed
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections GPC BIOTECH AG (DE) 2007-05-31 US disclosed
EP-1673346-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC Biotech AG (DE) 2006-06-28 EP disclosed
WO-2005040125-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS GPC BIOTECH AG (DE) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123537-A1 Quinazoline derivatives for the treatment of herpesviral infections IRF3, PML, TPMT EGFR 1445/4885FADS1 4484/4885LCK 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.